What Is Non-Hodgkin's Lymphoma?

Title: What Is Non-Hodgkin's Lymphoma?Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 10/6/2021 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news

Related Links:

In this study, we investigated the methylation levels of CpGs in CpG islands spanning the promoter regions of the miR-17–92 cluster host gene and the TET2 gene and correlated them with the expression levels of TET2 mRNA and miR-92a-3p and miR-92a-5p mature miRNAs in NHL cell lines, tumour samples, and the whole blood gDNA of an NHL case control cohort. Increased expression of both miR-92a-3p and miR-92a-5p and aberrant expression of TET2 was observed in NHL cell lines and tumour tissues, as well as disparate levels of dysfunctional promoter CGI methylation. Both miR-92a and TET2 may play a concerted role in NHL malig...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Clin Lymphoma Myeloma Leuk. 2021 Oct 15:S2152-2650(21)02383-1. doi: 10.1016/j.clml.2021.10.003. Online ahead of print.ABSTRACTAggressive B-cell lymphomas including diffuse large B-cell lymphoma make up the majority of non-Hodgkin's lymphoma globally. While more than half of these patients can be cured with modern chemoimmunotherapy regimens, the outcomes of relapsed or refractory disease continue to be very poor. Despite significant developments in targeted cancer therapies and immuno-oncology, the attainability of a cure remained an elusive goal outside of incorporating high doses of chemotherapy followed by hematopoietic...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
Leuk Res Rep. 2021 Oct 24;16:100275. doi: 10.1016/j.lrr.2021.100275. eCollection 2021.ABSTRACTMonoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mAb, was the first immunotherapy ever used in cancer, and a current cornerstone of lymphoma therapies. Since, we saw development of humanized antibodies, next generations anti-CD20, mAbs targeting other markers on tumor cells (CD19 and CD22), its microenvironment (PD-1, CD47), antibody drug conjug...
Source: Cell Research - Category: Cytology Authors: Source Type: research
AbstractThe PI3K δ-inhibitor Idelalisib is approved for the treatment of Non-Hodgkin lymphoma. However, its use has been decreased within the last years due to deleterious infections such as cytomegalovirus and pneumocystis jirovecii. Here, we have investigated the effect of Idelalisib on human monocyte-derived den dritic cells (DCs) as important players in the induction of immune responses. We found that Idelalisib-treated DCs displayed impaired T cell stimulatory function. PI3Kδ inhibition during differentiation resulted in decreased Interleukin-12, Interleukin-13 and TNFα production by DCs after lipopo...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
In this study, we analyzed 10 years' worth of data from the nationwide database to determine the rates of coexisting malignancies and second primary cancers associated with uveal melanoma. The mean annual incidence of uveal melanoma was 1.1 per million. Approximately 43% of patients had coexisting cancers. The most common coexisting cancer was lung cancer (10%) followed by liver cancer (6%) and non-Hodgkin lymphoma (6%). In patients whose first cancer in their lifetime was uveal melanoma, the 10-year cumulative incidence of second primary cancers was 22% (95% confidence interval, 9-31%). The age- and sex-adjusted standard ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractHealth-related quality of life (HRQoL) is a multidimensional concept including physical, emotional, social, and cognitive functions, disease symptoms, and side effects of treatment. Differences in HRQoL due to gender, existence of comorbidities, and number of chemotherapy cycles are little explored in diffuse large B-cell lymphoma (DLBCL) survivors. Our objective was to investigate whether differences in HRQoL in function of these factors exist 1 year after the diagnosis of DLBCL. One hundred and one patients, enrolled in the RT3 (Real-Time Tailored Therapy) Study, answered self-administrated European Organization ...
Source: Annals of Hematology - Category: Hematology Source Type: research
This article presents a review of Hodgkin lymphoma and non-Hodgkin lymphoma. These two common haematology diagnoses are frequently suspected by GPs and non-cancer professionals, and subsequently treated by haematologists and chemotherapy outpatient departments across the country. It is therefore important for all health professionals, including nurses in all settings, to be aware of the main characteristics of both of these lymphomas. There are strong similarities and striking differences between the disease processes, the presenting symptoms, prognostics and treatment pathways. The age of presentation in each is markedly ...
Source: British Journal of Nursing - Category: Nursing Authors: Source Type: research
CONCLUSION: Approximately 11% of patients with FA and 14% of patients with AT develop cancer by age 18 years.PMID:34597127 | DOI:10.1200/JCO.21.01495
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma